UC Research Reveals Key Cellular Function
The same enzyme that ensures cells undergo normal, programmed death is also necessary for proper formation of the embryo, according to an article that appeared in a December issue of the
Proceedings of the National Academy of Sciences
(PNAS).
Without programmed death, or apoptosis, cells would continue to proliferate indefinitely, leading to cancerous tumors. During programmed or normal cell death, a series of events leads to the eventual consumption of the cell by roving sentinels. One important step is the release of an enzyme called endonuclease G from the mitochondria inside the cell and its transport to the nucleus of the cell where it cleaves apart the DNA and the cell dies.
Jianhua Zhang, PhD, and Ming Xu, PhD, both faculty members at the UC Department of Cell Biology, Neurobiology and Anatomy, and colleagues investigated the role of this enzyme by developing strains of mice that were unable to produce the enzyme endonuclease G. Mice missing one copy of the gene had cells that were resistant to normal cell death or apoptosis.
Although this enzyme has been implicated in the replication of mitochondrial DNA, the numbers of mitochondrial DNA were the same in mutant and wild-type mice. Interestingly, the researchers were unable to produce mice missing both copies of the endonuclease G gene. Dr. Zhang and Dr. Xu said endonuclease G may play an essential role in remodeling the structure of the developing embryo through apoptosis, from a solid ball of cells to a hollow one that is not viable.
Dr. Zhang and Dr. Xu's research study demonstrates how this enzyme confers life and death. Results of their study were reported in the PNAS article #03-6393 and titled "Endonuclease G is required for early embryogenesis and normal apoptosis in mice."
Tags
Related Stories
UC radiation oncologist speaks with Local 12 news about clinical trial for head and neck cancer treatment
August 10, 2026
Dr. Sara Medek, a UC radiation oncology professor, speaks with Local 12 news about a new clinical trial aimed at reducing radiation in certain areas while still treating cancer effectively but with fewer painful side effects.
Cancer Center director charts future based on collaboration, AI
August 10, 2026
David Gius, MD, PhD, was featured in a Cincinnati Business Courier article and The Cancer Letter’s “The Directors" podcast discussing his priorities and goals as he recently took the helm as director of the University of Cincinnati Cancer Center.
Bidirectional link between oral, kidney health calls for patient education, access
August 4, 2026
Despite growing awareness of the connection between oral health and chronic health conditions, patient awareness and access to dental care remain limited, according to University of Cincinnati experts who recently spoke with Healio | Nephrology News & Issues.